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The aim of this study was to assess the involvement of
multipotential progenitor cells in the pathogenesis of Mooren's
ulcer using immunohistochemical staining techniques. Tissue
specimens were collected from 3 Mooren's ulcer patients who
underwent lamellar keratectomy. Immunohistochemical staining
patterns were analyzed using antibodies: CD34, c-kit, STRO-1,
CD45RO, VEGF and α-SMA. Strong positive CD34, c-kit and
STRO-1 cells were revealed in Mooren's ulcer specimens,
especially in the superficial stroma. A few weakly expressed
CD34 stroma cells were seen in normal limbal cornea but no
immunoreactivity for c-kit and STRO-1 could be found.
CD45RO positive T cells were found to have infiltrated in
Mooren's ulcer. The immunostaining pattern of VEGF and α-
SMA was closely correlated with the degree of expression and
the number of CD34 positive cells. Bone marrow-derived
multipotential progenitor cells may be involved in the patho-
genesis of Mooren's ulcer by synergizing with other factors to
amplify autoimmune destructive reactions and to contribute to
the regeneration process. Specific therapeutic strategies that
target the role of these cells in the disease are warranted.
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INTRODUCTION
First described by Bowman in 1849,
1 Mooren's
ulcer, also known as chronic serpiginous ulcer
and ulcer rodens, is a chronic painful corneal
ulceration which begins in the peripheral region
of the cornea with a steep, undetermined leading
edge and spreads both around and centrally to
affect the whole cornea.
2-4 Due to the rarity of
Mooren's ulcer, no controlled and few prospective
studies of the treatment of this condition have
been conducted. It is always refractory to avail-
able therapies, and results in severe visual
morbidity.
The pathogenesis of Mooren's ulcer is not well
understood. There are substantial evidences sug-
gesting that it is an autoimmune process, with
both cell-mediated and humoral components.




expression of HLA class II molecules in the cornea
and conjunctiva adjacent to the ulcers.
8 Cornea-as-
sociated antigen (Co-Ag) has also been found in
patients' sera.
9 The role of co-stimulation in T cell
activation has received significant attentions in the
last decade and there is little doubt today that T
cell function plays a critical role in autoimmunity
of Mooren's ulcer.
10-12 However, the mechanism
which instigates this autoimmune response is still
unclear. Currently, there is some evidence sup-
porting the hypothesis that antibodies to cornea
antigens are produced primarily in response to
tissue damage brought about by the disease,
rather than playing a critical role in the initiation
of the pathology of the ulcer.
13 Other additional
factors must be present, even if an association
does exist between some of proposed triggers and
Mooren's ulcer.
The local manifestation of the systemic disease
results in stromal coalescence, and leaves a
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scarred, vascularized cornea bed. Perforation sel-
dom occurs in Mooren's ulcer because the regen-
eration process occurs simultaneously. Wound
healing processes, including postnatal neovas-
cularization, have been thought to result exclu-
sively from proliferation and migration of pre-
existing bone marrow multipotential mesen-
chymal and endothelial progenitor cells.
14-16 This
finding led us to our research inquiry of better
understading the mechanisms of this rare condi-
tion from the systemic standpoint. The human
hematopoietic progenitor cell antigen CD34 is
known to be synthesized and expressed by certain
cells of hematopoietic lineage.
17,18 Stained tissue
for CD34 is usually associated with vascular
sprouting during vascularization.
19 STRO-1 has
been recently shown to differentiate into multiple
mesenchymal lineages.
20 C-kit is also a hemato-
poietic progenitor marker and co-expressed with
mesenchymal lineages of activated bone marrow
stem cells.
21 The studies we report herein were
carried out by using progenitor cell specific anti-
bodies to determine if they were involved in the
pathogenesis of Mooren's ulcer.
MATERIALS AND METHODS
Materials
Three patients with unilateral Mooren's ulcer
having no other pathologic features were re-
cruited from the Department of Ophthalmology,
Youngsan Hospital, Choong-Ang University
(Seoul, Korea). Clinical descriptions and photo-
graphs enabled the diagnosis of Mooren's ulcer to
be confirmed in these patients. Informed consent
was obtained from all participants for the use of
tissue. Tissue specimens were collected from cres-
cent-shaped lamellar keratectomy before lamellar
corneoscleral allograft was performed in the in-
volved area.
Immunohistochemical staining
Immediately after each surgery, some part of
the excised tissue was snap frozen after embed-
ment in optimal-cutting-temperature (O.C.T.)
compound (Tissue Tek; Miles, Naperville, IL,
U.S.A), and the other part was fixed in 10%
neutral buffered formalin, and then embedded in
paraffin. Several sets of serial 4 to 6 m cryostat μ
sections from each specimen were placed on
gelatinized slides, air dried, and then fixed in cold
acetone and rinsed in Tris-buffered saline. Paraffin
sections were deparaffinized in xylene and de-
scending ethanol series. An immunohistochemical
study was carried out using a labeled strep-
tavidin-binotin technique (Histostain-plus Kit;
Zymed, South San Francisco, CA, U.S.A.). A panel
of primary antibodies for the detection of stem
cell surface antigens, including the following:
polyclonal goat antihuman CD34, c-kit (Santa
Cruz Biotechnology, Santa Cruz, CA, U.S.A.),
monoclonal mouse anti-human STRO-1 (DSHB,
IA, U.S.A.), monoclonal mouse anti-human α-
Smooth muscle actin (α-SMA, NeoMarkers, CA,
U.S.A.), monoclonal mouse anti-human CD45RO
(DAKO Corporation, CA, U.S.A.), polyclonal rab-
bit anti-human vascular endothelial growth factor
(VEGF, Zymed, South San Francisco, CA, U.S.A.)
were used. The specimen was incubated in bio-
tinylated secondary antibody for 1 hour at room
temperature, and then incubated for 30 minutes
with peroxidase- conjugaed sterptavidin. The pre-
sence of peroxidase was revealed by adding sub-
strate-chromogen (3-amino-9-ethycar bazole) solu-
tion. Sections were counterstained with hematoxi-
lin.
The number of CD34, VEGF and α-SMA posi-
tive cells was counted from three different regions
of each sample under 400× magnification.
RESULTS
All 3 patients had a stable and relatively regular
ocular surface after lamellar keratectomy, confir-
med by topographic examination. Preoperative
external photography of 1 selected case, who had
significant marginal ulceration with a thinned,
vascularized cornea base, is shown in Fig 1. Visual
acuity was improved from 20/40 to 20/20 on the
initial consultation.
Results from light microscopy of the cornea
from Mooren's ulcer patients revealed a focal
absence of the corneal epithelium and Bowman's
layer. In all the specimens, strong positive immu-Pathogenesis of Mooren's Ulcer
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noreactivity to CD34, c-kit and STRO-1 could be
detected in the patients' cornea stroma, especially
in the superficial stroma. CD34 was positively ex-
pressed by vascular endothelial cells, some stroma
cells, and epithelial cells. Some c-kit and STRO-1
positive cells exhibited the typical spindle-shape
(Fig. 2A, 2B, 2C). Upregulated activated CD45
positive T cells infiltrated the Mooren's ulcer
specimens, especially in the superficial region of
stroma (Fig. 3A); Strong positive VEGF staining
pattern was shown in vascular endothelial cells, a
few epithelial cells, and some scattered cells in
stroma (Fig. 3B); α-SMA was positively expressed
only in the vessel wall of vascularized stroma
(Fig. 3C). Similar immunostaining patterns were
found among CD34 (18.50 ± 3.87 positive cells),
VEFG (16.75 ± 3.78 positive cells) and α-SMA (7.25
± 2.21 positive cells) with strong positive expres-
sion for small vessels.
DISCUSSION
Despite accumulating evidence that cell-medi-
ated and humoral immunomechanisms are
present in Mooren's ulcer, it is uncertain that they
are involved directly in the pathogenesis of the
disease. It is possible that they simply accompany
corneal destruction that is caused by another
mechanism.
22 In contrast to some other forms of
peripheral ulcerative keratitis, a clinical charac-
teristic of Mooren's ulcer is the involvement of the
limbus, where stem cells exist.
23,24 With the disease
gradually running its course, healing and vascu-
larization follow, which then results in a typically
scarred, vascularized cornea that may be thinned
to less than half of its original thickness. This is
a result of the systemic regeneration process.
Because endothelial progenitor cells that contri-
Fig. 1. Slit lamp photograph of Mooren's ulcer shows
advanced corneal ulceration involving corneal center with
vascularized corneal base, corneal thinning and adjacent
conjuctival inflammation.
Fig. 2. Immunohistochemical staining of the limbal cornea
of Mooren's ulcer for antibodies CD34 (A), c-kit (B) and
STRO-1 (C). CD34, c-kit and STRO-1 immunoreactivity
was strongly positive in the superficial stroma of
Mooren's ulcer cornea (Original magnification × 200).
A
B
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bute to neovascularization are differentiated from
CD34 positive cells and mobilized from bone
marrow, and scarred cornea mainly consists of
differentiated fibroblasts,
25 we hypothesize that
bone marrow derived multipotential progenitor
cells may be involved in co-existing cornea de-
struction and regeneration during the course of
the disease.
VEGF has been identified with vasculogenesis
26
and α-SMA stains smooth muscle cells in vessel
walls.
27 Leukocyte antigen CD34 is the common
surface marker for hematopoietic progenitor cells
and endothelium.
28 Endothelial cell surface receptors
that appear early in development are VEGF re-
ceptor and CD34.
29 The c-kit protooncogene has
been identified as a member of the receptor-
tyrosine kinase family. When c-kit receptors,
which are produced by mesenchymal cells, bind
to human stem cell factor (SCF) (also termed c-kit
ligand) it will augment the proliferation of primi-
tive bone marrow progenitor cells and differen-
tiated mast cells.
30-32 The fibroblast-like stem cells
express the c-kit, suggestive of mesenchymal dif-
ferentiation.
21 STRO-1 is a monoclonal antibody
that was shown to recognize all the clonogenic
mesenchymal stem cells in human bone marrow
fibroblast-like cells and to various nonhemato-
poietic progenitor cells.
33,34 Hematopoietic and
mesenchymal stem cells detected in Mooren's
ulcer cornea in this study may be considered to
be evidence of the involvement of bone marrow-
derived progenitor cells in the pathogenesis of
Mooren's ulcer. Some VEGF and α-SMA positive
cells may differentiate from CD34 positive pro-
genitor cells.
The mechanism proposed for the pathogenesis
of Mooren's ulcer postulates that circulating im-
mune complexes are deposited in the limbal ves-
sels, resulting in an immune-mediated vasculitis
with vessel wall damage and leakage of inflam-
matory cells and proteins.
35,36 Inflammatory cells
can release cytokines such as interleukin (IL)-1β,
-6,-8, tumor necrosis factor-α (TNF-α) and pro-
teases which destroy corneal stroma.
37-39 This im-
mune response will act as a long term signal to
stimulate bone marrow quiescent multipotential
progenitor cells and chemotaxis to the wounded
limbal area to participate in the wound healing
and regenerative process. It is conceivable that
some factors or combinations of certain cytokines,
especially IL-1 and TNF-α which are capable of
stimulating keratocytes to release chemotactic
factors (e.g.IL-8 and granulocyte colony stimu-
lating factor (GM-CSF)), will activate these local-
ized stem cells and simultaneously activate more
Fig. 3. Patterns of immunostaining of the limbal cornea
of Mooren's ulcer with CD45RO (A), VEGF (B) and α-
SMA (C). CD45RO positive T cells infiltrated in the su-
perficial stroma (A). Vascular endothelial cells and some
stroma cells stained with VEGF (B). -SMA positive cells α
located in the vessel wall (Original magnification × 200).
A
B
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neutrophils.
40 Following activation, multipotential
progenitor cells gain their ability to differentiate
into vascular endothelial cells, fibroblasts, and
cornea epithelial cells, therefore contributing to
cornea vascularization scarring and re-epitheli-
zation. In contrast, differentiated fibroblasts, such
as capillary endothelial cells, which are capable of
producing enzymes that can initiate the degrada-
tion of type I collagen, are involved in the destruc-
tive process.
Activated progenitor cells can produce numer-
ous cytokines such as IL-6, IL-11, macrophage
colony stimulating factor (M-CSF), GM-CSF and
SCF.
41 These cytokines can further activate more
limbal stem cells, neutrophils and macrophages.
Activated neutrophils will release neutrophil cal-
granulin C (CaGC), because the amino acid of cor-
nea-associated antigen (Co-Ag) is found to be
identical to that of CaGC.
42 It is possible to pos-
tulate that progenitor cells indirectly amplify the
autoimmune response. In addition, neutrophils
may actively participate in the destructive process
of Mooren's ulcer by releasing a variety of
collagenase.
40
In summary, we confirmed the expression of
the multipotential progenitor cells and other coop-
erating factors in Mooren's ulcer. The origin of
multipotential stem cells is presumed to be in the
bone marrow. Although the detailed mechanisms
by which stem cells participate in multi-pathway
corneal inflammatory and autoimmune disease
require further study, our findings elucidate other
molecular mechanisms involved in the process
and may help in achieving a more comprehensive
view of Mooren's ulcer. It is anticipated that this
new knowledge will lead to the development of
specific therapeutic strategies that could target
critical steps in the pathogenesis of this disease.
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